Apogee Therapeutics Inc. (APGE)
NASDAQ: APGE
· Real-Time Price · USD
38.11
-0.01 (-0.03%)
At close: Aug 15, 2025, 10:01 AM
-0.03% (1D)
| Bid | 37.93 |
| Market Cap | 2.27B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -150.05M |
| EPS (ttm) | -4.14 |
| PE Ratio (ttm) | -9.2 |
| Forward PE | -6.42 |
| Analyst | Buy |
| Ask | 38.21 |
| Volume | 52,454 |
| Avg. Volume (20D) | 893,432 |
| Open | 38.29 |
| Previous Close | 38.12 |
| Day's Range | 37.93 - 38.63 |
| 52-Week Range | 26.20 - 63.50 |
| Beta | 1.44 |
About APGE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol APGE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for APGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-17.32%
APGE stock has given up its prior gain. Apogee The...
Unlock content with
Pro Subscription
1 month ago
-17.32%
Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.
1 month ago · proactiveinvestors.com
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drugApogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The tr...
